TY - JOUR
T1 - Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
AU - Nishino, Mizuki
AU - Hida, Tomoyuki
AU - Kravets, Sasha
AU - Dahlberg, Suzanne E.
AU - Lydon, Christine A.
AU - Hatabu, Hiroto
AU - Johnson, Bruce E.
AU - Awad, Mark M.
N1 - Funding Information:
This work was supported by the National Institutes of Health R01CA203636 (NCI) .
Funding Information:
Awad: Consultant to AstraZeneca, AbbVie, Boehringer-Ingelheim, Merck, Pfizer, Genentech. Research grant from the Conquer Cancer Foundation of the American Society of Clinical Oncology ; and the International Association for the Study of Lung Cancer .
Funding Information:
Hatabu: Reserch funding from Canon Inc. , Canon Medical Systems , and Konica-Minolta ; Consultant to Toshiba Medical Systems, and Mitsubishi Chemical Inc.
Funding Information:
Nishino: Consultant to Daiichi Sankyo, AstraZeneca; Research grant from Merck , Canon Medical Systems , AstraZeneca ; Honorarium from Roche .
Funding Information:
Nishino: Consultant to Daiichi Sankyo, AstraZeneca; Research grant from Merck, Canon Medical Systems, AstraZeneca; Honorarium from Roche.Hatabu: Reserch funding from Canon Inc., Canon Medical Systems, and Konica-Minolta; Consultant to Toshiba Medical Systems, and Mitsubishi Chemical Inc.Johnson: Research support: Canon Medical Systems and Novartis; Post Marketing Royalties for EGFR Mutation testing; Dana-Farber Cancer Institute.Awad: Consultant to AstraZeneca, AbbVie, Boehringer-Ingelheim, Merck, Pfizer, Genentech. Research grant from the Conquer Cancer Foundation of the American Society of Clinical Oncology; and the International Association for the Study of Lung Cancer.This work was supported by the National Institutes of HealthR01CA203636 (NCI).
Publisher Copyright:
© 2020 The Authors
PY - 2020
Y1 - 2020
N2 - Purpose: The purpose of the study is to investigate volumetric tumor burden dynamics and tumor growth rates in ALK-rearranged advanced NSCLC patients during crizotinib monotherapy. Methods: The study included 44 ALK-rearranged advanced NSCLC patients treated with crizotinib monotherapy as their initial ALK-directed therapy, who had at least one measurable lung lesion and at least two follow-up CT scans, and experienced tumor volume increase while on crizotinib. The tumor volume (in mm3) of the dominant lung lesion was measured on serial CT scans during therapy for analysis of tumor growth rates after the volume nadir. Results: A total of 231 volume measurements from the nadir to the end of crizotinib therapy or the last follow-up in 44 patients were analyzed in a linear mixed-effects model, fitting time (in months since baseline) as a random effect. When measured from the volume nadir, the tumor growth rate of the logarithm of tumor volume (logeV) was 0.04/month (SE = 0.012, P = 0.0011) in the unadjusted model. When adjusted for the baseline volume (logeV0), the growth rate was again 0.04/month (SE = 0.011, P = 0.0004). When adjusted for clinical variables and logeV0, the growth rate was 0.045/month (SE = 0.012, P = 0.0002), indicating that the tumor growth rate after nadir in this cohort remains very close to 0.04/month regardless of logeV0 or clinical factors. Conclusions: Tumor volume growth rate after nadir in ALK-rearranged NSCLC patients treated with crizotinib was obtained, providing objective reference values that can inform physicians when deciding to keep their patients on ALK directed therapy with slowly progressing lung cancer.
AB - Purpose: The purpose of the study is to investigate volumetric tumor burden dynamics and tumor growth rates in ALK-rearranged advanced NSCLC patients during crizotinib monotherapy. Methods: The study included 44 ALK-rearranged advanced NSCLC patients treated with crizotinib monotherapy as their initial ALK-directed therapy, who had at least one measurable lung lesion and at least two follow-up CT scans, and experienced tumor volume increase while on crizotinib. The tumor volume (in mm3) of the dominant lung lesion was measured on serial CT scans during therapy for analysis of tumor growth rates after the volume nadir. Results: A total of 231 volume measurements from the nadir to the end of crizotinib therapy or the last follow-up in 44 patients were analyzed in a linear mixed-effects model, fitting time (in months since baseline) as a random effect. When measured from the volume nadir, the tumor growth rate of the logarithm of tumor volume (logeV) was 0.04/month (SE = 0.012, P = 0.0011) in the unadjusted model. When adjusted for the baseline volume (logeV0), the growth rate was again 0.04/month (SE = 0.011, P = 0.0004). When adjusted for clinical variables and logeV0, the growth rate was 0.045/month (SE = 0.012, P = 0.0002), indicating that the tumor growth rate after nadir in this cohort remains very close to 0.04/month regardless of logeV0 or clinical factors. Conclusions: Tumor volume growth rate after nadir in ALK-rearranged NSCLC patients treated with crizotinib was obtained, providing objective reference values that can inform physicians when deciding to keep their patients on ALK directed therapy with slowly progressing lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=85078296754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078296754&partnerID=8YFLogxK
U2 - 10.1016/j.ejro.2019.12.004
DO - 10.1016/j.ejro.2019.12.004
M3 - Article
AN - SCOPUS:85078296754
SN - 2352-0477
VL - 7
JO - European Journal of Radiology Open
JF - European Journal of Radiology Open
M1 - 100210
ER -
